These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37144288)

  • 1. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion.
    Ricci S; Azzari C; Amodio E; Castiglia P
    Expert Rev Vaccines; 2023; 22(1):447-456. PubMed ID: 37144288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age.
    Robertson CA; Jacqmein J; Selmani A; Galarza K; Oster P
    Hum Vaccin Immunother; 2024 Dec; 20(1):2426868. PubMed ID: 39555800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006-2010.
    Naidu L; Chiu C; Habig A; Lowbridge C; Jayasinghe S; Wang H; McIntyre P; Menzies R
    Commun Dis Intell Q Rep; 2013 Dec; 37 Suppl():S1-95. PubMed ID: 24410428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic characterization and estimated 4CMenB vaccine strain coverage of 284
    Efron A; Brozzi A; Biolchi A; Bodini M; Giuliani M; Guidotti S; Lorenzo F; Moscoloni MA; Muzzi A; Nocita F; Pizza M; Rappuoli R; Tomei S; Vidal G; Vizzotti C; Campos J; Sorhouet Pereira C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2378537. PubMed ID: 39037011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose.
    Peterson J; Drazan D; Moughan B; Maguire JD; Zolotas L; Maansson R; O'Neill R; Peyrani P; Jodar L; Gruber WC; Anderson AS; Beeslaar J
    Vaccine; 2025 Jan; 43(Pt 1):126469. PubMed ID: 39520893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial.
    Knuf M; Rämet M; Breinholt Stærke N; Bertrand-Gerentes I; Thollot Y; B'Chir S; Arroum H; Oster P
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052657. PubMed ID: 35445641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.
    Nolan T; Bhusal C; Beran J; Bloch M; Cetin BS; Dinleyici EC; Dražan D; Kokko S; Koski S; Laajalahti O; Langley JM; Rämet M; Richmond PC; Silas P; Tapiero B; Tiong F; Tipton M; Ukkonen B; Ulukol B; Lattanzi M; Trapani M; Willemsen A; Toneatto D;
    Lancet Infect Dis; 2024 Dec; ():. PubMed ID: 39647494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4CMenB journey to the 10-year anniversary and beyond.
    Abitbol V; Martinón-Torres F; Taha MK; Nolan T; Muzzi A; Bambini S; Borrow R; Toneatto D; Serino L; Rappuoli R; Pizza M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2357924. PubMed ID: 38976659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inequalities in the risk and prevention of invasive meningococcal disease in the United States - A systematic literature review.
    Begum S; Herrera-Restrepo O; Rolland C; Purushotham S; Andani A; Shah H; Kocaata Z
    Hum Vaccin Immunother; 2024 Dec; 20(1):2406613. PubMed ID: 39373020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
    Marshall HS; Lally N; Flood L; Phillips P
    Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia.
    Haidara FC; Umesi A; Sow SO; Ochoge M; Diallo F; Imam A; Traore Y; Affleck L; Doumbia MF; Daffeh B; Kodio M; Wariri O; Traoré A; Jallow E; Kampmann B; Kapse D; Kulkarni PS; Mallya A; Goel S; Sharma P; Sarma AD; Avalaskar N; LaForce FM; Alderson MR; Naficy A; Lamola S; Tang Y; Martellet L; Hosken N; Simeonidis E; Welsch JA; Tapia MD; Clarke E
    N Engl J Med; 2023 May; 388(21):1942-1955. PubMed ID: 37224196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2003 to 2006.
    Menzies R; Turnour C; Chiu C; McIntyre P
    Commun Dis Intell Q Rep; 2008 Jun; 32 Suppl():S2-67. PubMed ID: 18711998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT.
    Martinón-Torres F; Bertrand-Gerentes I; Oster P
    Expert Rev Vaccines; 2021 Sep; 20(9):1123-1146. PubMed ID: 34365870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study.
    Dhingra MS; Namazova-Baranova L; Arredondo-Garcia JL; Kim KH; Limkittikul K; Jantarabenjakul W; Perminova O; Kobashi IAR; Bae CW; Ojeda J; Park J; Chansinghakul D; B'Chir S; Neveu D; Bonaparte M; Jordanov E
    Epidemiol Infect; 2021 Apr; 149():e90. PubMed ID: 33814028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of vaccination strategies against meningococcal disease for children under nine years of age in China.
    Zhang H; Zhang H; Fang H
    Hum Vaccin Immunother; 2024 Dec; 20(1):2313872. PubMed ID: 38348600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
    Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2-55 Years) in Japan: a Phase III Randomized Study.
    Matsuoka O; Ujiie M; Kikuchi H; Otake S; Chansinghakul D; Inoue T; Varghese K; Sirisuphmitr N; Hashiguchi T; Zambrano B; Nakama T; Frago C; Jordanov E; Dhingra MS
    Jpn J Infect Dis; 2023 May; 76(3):174-182. PubMed ID: 36724939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Annual immunisation coverage report 2021.
    Hull B; Hendry A; Dey A; Brotherton J; Macartney K; Beard F
    Commun Dis Intell (2018); 2023 Aug; 47():. PubMed ID: 37817316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disparate kinetics in immune response of two different
    Martinón-Torres F; Salamanca de la Cueva I; Horn M; Westerholt S; Bosis S; Meyer N; Cheuvart B; Virk N; Jakes RW; Duchenne M; Van den Steen P
    Hum Vaccin Immunother; 2024 Dec; 20(1):2342630. PubMed ID: 38687024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in children aged 10-12 years: phase III randomized trial complementary analysis of immune persistence 3-6 years after priming.
    Peterson J; Galarza K; Bchir S; Zocchetti C; Bertrand-Gerentes I; Zambrano B
    Pediatr Res; 2024 Dec; ():. PubMed ID: 39672823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.